Acid Reducers, Drug-Drug Interactions, and Setting Expectations for Response

The moderator asks about patients taking acid reducers. One panelist explains that revumenib has no restriction, while ziftomenib should ideally be avoided or separated. The discussion moves to CYP3A inhibitors, including the dose change with strong inhibitors and keeping an updated medication list. The panelists then discuss setting expectations, including that response takes about 2 months, and then delving into discussion of the AUGMENT-101 response rates. With new data emerging, one panelist describes how they communicate expectations with community colleagues on response and also how they manage their own practice and counsel their patients.